Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? No

Internal and Emergency Medicine

Volumn 3, Issue 3, 2008, Pages 197-200

  Finazzi, Guido ^a   Gerosa, Maria ^b,c   Chighizola, Cecilia ^b,c   Meroni, Pier Luigi ^b,c  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 49649100338     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-008-0169-4     Document Type: Review

References (15)

1. 1. S Miyakis MD Lockshin T Atsumi 2006 International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome J Thromb Haemost 4 295 306 16420554 10.1111/j.1538-7836.2006.01753.x 1:CAS:528:DC%2BD28XisVSjuro%3D Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 4:295–306
2. 2. G Finazzi R Marchioli V Brancaccio 2005 A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) J Thromb Haemost 3 848 853 15869575 10.1111/j.1538-7836.2005.01340.x 1:CAS:528:DC%2BD2MXltlOitL4%3D Finazzi G, Marchioli R, Brancaccio V et al (2005) A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3:848–853
3. 3. C Patrono B Coller GA FitzGerald 2004 Platelet-active drugs: the relationship among dose, effectiveness and side effects. The seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 234S 264S 15383474 10.1378/chest.126.3_suppl.234S 1:CAS:528:DC%2BD2cXptV2msLo%3D Patrono C, Coller B, FitzGerald GA et al (2004) Platelet-active drugs: the relationship among dose, effectiveness and side effects. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:234S–264S
4. 4. R Landolfi R Marchioli J Kutti 2004 Efficacy and safety of low-dose aspirin in polycythemia vera N Engl J Med 350 114 124 14711910 10.1056/NEJMoa035572 1:CAS:528:DC%2BD2cXjs1aluw%3D%3D Landolfi R, Marchioli R, Kutti J et al (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350:114–124
5. 5. JA Giron-Gonzales E Garcia del Rio C Rodriguez 2004 Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals J Rheumatol 31 1560 1567 Giron-Gonzales JA, Garcia del Rio E, Rodriguez C et al (2004) Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 31:1560–1567
6. 6. R Forastiero M Martinuzzo G Pombo 2005 A prospective study of antibodies to β2-glycoprotein I and prothrombin and risk of thrombosis J Thromb Haemost 3 1231 1238 15946213 10.1111/j.1538-7836.2005.01295.x 1:CAS:528:DC%2BD2MXms1aqsr4%3D Forastiero R, Martinuzzo M, Pombo G et al (2005) A prospective study of antibodies to β2-glycoprotein I and prothrombin and risk of thrombosis. J Thromb Haemost 3:1231–1238
7. 7. NM Shah MA Khamashta T Atsumi 1998 Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients Lupus 7 3 6 9493141 10.1191/096120398678919624 1:STN:280:DyaK1c7lsVWrsQ%3D%3D Shah NM, Khamashta MA, Atsumi T et al (1998) Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 7:3–6
8. 8. E Somers LS Magder M Petri 2002 Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus J Rheumatol 29 2531 2536 12465147 1:CAS:528:DC%2BD3sXntFyh Somers E, Magder LS, Petri M (2002) Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 29:2531–2536
9. 9. G Finazzi V Brancaccio M Moia 1996 Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies. A four-year prospective study from the Italian registry Am J Med 100 530 536 8644765 10.1016/S0002-9343(96)00060-5 1:STN:280:BymB2c%2FhtlA%3D Finazzi G, Brancaccio V, Moia M et al (1996) Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies. A four-year prospective study from the Italian registry. Am J Med 100:530–536
10. 10. MA Khamashta MJ Cuadrado F Mujic 1995 The management of thrombosis in the antiphospholipid-antibody syndrome N Engl J Med 332 993 997 7885428 10.1056/NEJM199504133321504 1:STN:280:ByqC1M7mtlA%3D Khamashta MA, Cuadrado MJ, Mujic F et al (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993–997
11. 11. M Kaul D Erkan L Sammaritano 2007 Assessment of the 2006 revised antiphospholipid syndrome classification criteria Ann Rheum Dis 66 927 930 17337473 10.1136/ard.2006.067314 Kaul M, Erkan D, Sammaritano L et al (2007) Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis 66:927–930
12. 12. KS Ginsburg MH Liang L Newcomer 1992 Anticardiolipn antibodies and the risk for ischemic stroke and venous thrombosis Ann Intern Med 117 997 1002 1443986 1:STN:280:ByyD2szjs1Q%3D Ginsburg KS, Liang MH, Newcomer L et al (1992) Anticardiolipn antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117:997–1002
13. 13. DG Wahl H Bounameaux P Moerloose de 2000 Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis Arch Intern Med 160 2042 2048 10888978 10.1001/archinte.160.13.2042 1:STN:280:DC%2BD3czkslKmsg%3D%3D Wahl DG, Bounameaux H, de Moerloose P et al (2000) Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 160:2042–2048
14. 14. D Erkan MJ Harrison R Levy 2007 Aspirin for primary thrombosis prevention in the antiphospholipid syndrome Arthritis Rheum 56 2382 2391 17599766 10.1002/art.22663 1:CAS:528:DC%2BD2sXovFSgurs%3D Erkan D, Harrison MJ, Levy R et al (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome. Arthritis Rheum 56:2382–2391
15. 15. M Galli G Borrelli EM Jacobsen 2007 Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study Blood 110 1178 1183 17440049 10.1182/blood-2007-01-066043 1:CAS:528:DC%2BD2sXptFKmu7Y%3D Galli M, Borrelli G, Jacobsen EM et al (2007) Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 110:1178–1183